1.

Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura

Answer»

Both increased the PLATELET counts in HEALTHY subjects and in over two THIRDS of patients with ITP both before and after splenectomy; responses were maintained for at least 1 YEAR. Romiplostim and eltrombopag are now US Food and Drug Administration approved for the second-line treatment of patients with ITP.
I HOPE may I help you+×:+;{××÷+×



Discussion

No Comment Found

Related InterviewSolutions